Cancer-initiating cells as target for prevention of recurring disease etiology: Role of these malignant putative progenitor cells in relapse or metastasis of human cervical carcinoma

Journal of Stem Cells

Volumn 8, Issue 3-4, 2013, Pages 233-251

  Ramdass, Bharathi ^a   Chowdhary, Abhay ^b   Koka, Prasad S ^a,b  

^a POORNAPRAJNA INSTITUTE OF SCIENTIFIC RESEARCH   (India)

^b Haffkine Institute for Training Research and Testing India   (India)

Author keywords

Cancer stem cell; Cervical cancer; HPV; Vaccination

Indexed keywords

TUMOR MARKER;

CANCER STEM CELL; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; PREVENTION AND CONTROL; RECURRENT DISEASE; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

BIOMARKERS, TUMOR; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; RECURRENCE; UTERINE CERVICAL NEOPLASMS;

EID: 84900404096     PISSN: 15568539     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. H. Zur Hausen. "Papillomaviruses and Cancer: from basic studies to clinical applications". Nature Rev. Cancer, vol. 2, pp. 342-350, 2002.
2. L.L. Villa. "Human Papillomaviruses and cervical cancer". Adv Cancer Res, pp. 321-341, 1997.
3. H. Zur hausen and E.M. de Villers. "Human Papillomaviruses". AnnRev Microbiol.vol. 48, pp.427-447, 1994.
4. P.M. Howley. In "Fields' Virology" (B.N. Fields, D. M. Kneip, and PM. Howley, Eds), Vol 2, pp. 2045-2076. Lippincott-Raven, Philadelphia, 1996.
5. H. Delius and B. Hofmann. "Primer-directed sequencing of human papillomavirus types". Curr Top Microbiol Immunol. Vol 186, pp.13-31, 1994.
6. E.M. De Villers. "Human pathogenic papillomavirus types: an update".Curr. Top. Microbiol. Immunol, vol. 186, pp. 1-12, 1994.
7. N. Munoz, X. Castellsague, A.B.de Gonzalez, L. Gissmann. Chapter 1: "HPV in the etiology of human cancer". Vaccine: pp. 1-10, 2006.
8. H. Len, L.L. Villa, F. Marziona, M. Hilgarth, H.G. Hilemans, and G. Sauer. "Physical State and biological activity of human papillomavirus genomes in precancerous lesions of the female genital tract". J. Gen. Virol., vol. 69, pp. 187-196,1988.
9. A.P. Cullen, R. Reid, M. Campion, and A.T. Lorincz. "Analysisof the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm". J. Virol., vol 65, no.2, pp. 606-612, 1991.
10. H.U. Bernard, S.Y. Chan, and H. Delius. Evolution of papillomaviruses". Curr. Top. Microbiol. Immunol, vol. 186, pp. 33-54, 1994.
11. J. Zhou, J. Doorbar, X.Y Sun, L.V. Crawford, C.S. McLean, and I.H. Frazer. "Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein". Virology, vol. 185, no.2, pp. 625-632,1991.
12. M. Durst, R.T. Dzarlieva-Petrusevska, P. Boukamp, N.E. Fusenig, and L. Gissmann. "Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA". Oncogene, vol.1, no.3, pp. 251-256, 1987.
13. L. Pirisi, S. Yasumoto, M. Feller, J. Doniger, and J.A. DiPaolo. "Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA". J. Virol, vol. 61, no.4, pp. 1061-1066, 1987.
14. R. Schlegel, W.C. Phelps, Y.L. Zhang, and M. Barbosa. "Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma". EMBO J, vol. 7, no.10, pp. 3181-3187, 1988.
15. C.D. Woodworth, P.E. Bowden, J. Doniger, L. Pirisi, W. Barnes, W.D. Lancaster, and J.A. Di Paolo "Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA". Cancer Res, vol. 48, no.16, pp. 4620-4628, 1988.
16. K. Munger, W.C. Phelps, V. Bubb, P.M. Howley, and R. Schlegel. "The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes". J. Virol, vol. 63, no.10, pp. 4417-4421, 1989.
17. R. Reid. "Genital warts and cervical cancer. II. Is humanpapillomavirus infection the trigger to cervical carcinogenesis?". Gynecol Oncol, vol.15, pp. 239-252,1983.
18. E.C. Goodwin and D. DiMaio. "Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways". Proc Natl Acad Sci. USA., vol. 97, pp.12513-12518, 2000.
19. H. zurHausen. "Papillomaviruses causing cancer: evasion from host -cell control in early events in carcinogenesis". J Natl Cancer Inst, vol. 92, pp.690-698, 2000.
20. T.T. Maliekal, J. Bajaj, V. Giri, D. Subramanyam, and S. Krishna. "The role of Notch Signaling in human cervical cancer: implications for Solid tumors". Oncogene, vol.27, pp. 5110-5114, 2008.
21. D. Feng, C. Peng, C. Li, Y. Zhou, M. Li, B. Ling, H. Wei, and Z. Tian. "Identification and Characterization of cancer stem like cells from primary carcinoma of the Cervix Uteri". Oncology Reports, vol. 22, pp. 1129-1134, 2009.
22. Nandakumar, T. Ramnath and M. Chaturvedi. "The magnitude of cancer cervix in India". Indian J. Med. Res, vol. 130, pp. 219-221, 2009.
23. J. Meija-Gomez and X. Sastre-Garau. "Uterine Cervix carcinoma: Recent Biological Data and Update for improving follow -up and treatment". IMAJ, vol. 14, pp. 700-704, 2012.
24. B. Daniel, G. Mukherjee, L. Seshadri, E. Vallikad, S. Krishna. "Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasialeisons analysed by PCR". J. Gen Virol, vol 76, 2589-93, 1995.
25. B. Daniel, A. Rangarajan, G. Mukherjee, E. Vallikad, S. Krishna. "The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions". J Gen Virol 78, 1095-1101, 1997.
26. K. Veeraraghavalu, M. Pett, R.V. Kumar, P. Nair, A. Rangarajan, M.A. Stanley and S. Krishna. "Papillomavirus mediated neoplastic progression is associated with reciprocal changes in Jagged1 and Manic fringe expression linked to notch activation". J Virol, vol. 78, pp. 8687-8700, 2004.
27. Rangarajan, R. Syal, S. Selvarajah, O. Chakrabarti, A. Sarin and S. Krishna. "Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt". Virology, vol. 286, pp. 23-30, 2001.
28. O. Chakrabarti, K. Veeraraghavalu, V. Tergaonkar, Y. Liu, E.J. Androphy, M.A. Stanley and S. Krishna. "Human papillomavirus type 16 E6 amino acid 83 variants enhance E6 mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras". J Virol, vol. 78, pp. 5934-5945, 2004.
29. B. Ramdass, T.T. Maliekal, S. Lakshmi, M. Rehman, P. Rem, P. Nair, G. Mukherjee, B.K.M. Reddy, S. Krishna, and M.R. Pillai. "Coexpression of Notch1 and NF-κB Signaling pathway components in human cervical cancer progression". Gynecol Oncol, vol. 104, pp. 352-361, 2007.
30. S. Srivastava, B. Ramdass, S. Nagarajan, M. Rehman, G. Mukherjee and S. Krishna. "Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression". Br. J. Cancer, vol. 102,no. 1, pp. 196-205, 2010.
31. D. Subramanyam and S. Krishna. "c-Myc substitutes for Notch1-CBF1 functions in cooperative transformation with papillomavirus oncogenes". Virology, vol. 347, no.1, pp. 191-198, 2006.
32. J. Bajaj, T.T. Maliekal, E. Vivien, C. Pattabiraman, Srivastava S, H. Krishnamurthy, V. Giri, D. Subramanyam, and S. Krishna. "Notch Signaling in CD66+ cells drives the progression of Human Cervical cancers". Cancer Res, vol. 71 no.14, pp. 4888-4897, 2011.
33. V.C. Mak, M.K. Siu, O.G. Wong, K.K. Chan, H.Y. Ngan, A.N. Cheung. "Dysregulatedstemness related genes in gynecological malignancies". Histol Histopathol, vol.27, no. 9, pp. 1121-30, 2012.
34. J. Lopez, A. Poitevin, V. Mendoza-Martinez, C. Perez-Plasencia and A. Garcia-Carranca "Cancer initiating cells derived from established cervical cell lines exhibit stem cell markers and increased radioresistance". BMC Cancer, vol. 12, no. 48, pp. 1-14, 2012.
35. T. Yao, Q. Chen, B. Zhang, H. Zhou, Z. Lin. "The expression of ALDH1 in cervical carcinoma". Med. Sci. Monit, vol.17, no. 8, pp. 21-26, 2011.
36. Q.X. Rao, T.T. Yao, B.Z. Zhang, R.C. Lin, Z.L. Chen, H. Zhou, L.J. Wang, H.W. Lu, Q. Chen, N. Di, Z.Q. Lin. "Expression and functional role of ALDH1 in cervical carcinoma cells". Asian. Pac. J. Cancer. Prev, vol. 13, no.4, pp. 1325-31, 2012.
37. F. Wang, Y. Li, J. Zhou, J. Xu, C. Peng, F. Ye, Y. Shen, W. Lu, X. Wan, and X. Xie. "miRNA-375 is down regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1". American.J. pathol, vol. 179, no.5, pp. 2580-2588, 2011.
38. L. Rocha-Zavaleta, C. Huitron, J.R. Caceres-Cortes, J.A. Alvarado-Moreno, A. Valle-Mendiola, I. Soto-Cruz, B. Weiss-Steider, R. Rangel-Corona. "Interleukin-2 (IL-2) receptor-betagamma signalling is activated by c-Kit in the absence of IL2 or by exogenous IL-2 via jak3/STAT5 in human papillmavirus associated cervical cancer". Cell Signal, vol.16, no.11, pp. 1239-47, 2004.
39. A.K. Wege, W. Ernst, J. Eckl, B. Frankerberger, A.V. Zwerenz, D.N. Mannel, O. Ortmann, A. Kroemer, and G. Brockhoff. "Humanized tumor mice-A new model to study and manipulate the immune response in advanced cancer therapy". Int.J. Cancer, pp.1-13, 2011.
40. M.A. Brehm, L.D. Shultz and D.L. Greiner. "Humanized Mouse models to study Human diseases". Curr.Opin. Endocrinol. Diabetes Obes, vol. 17, no. 2, pp. 120-125, 2010.
41. Pearson T, Greiner DL and Shultz DL. "Humanized SCID Mouse Models for Biomedical Research". T. Nomura et al., (eds), Humanized Mice. Current Topics in Microbiology and Immunology, vol.324, pp. 25-42. Springer-Verlag Berlin Heidelberg, 2008.
42. -/-and C.B-17-SCID /bg Immunodeficient mice". Human Immunol, vol. 70, no. 10, pp. 790-802, 2009.
43. M. Zhang, P. Dias, B. Minev, and P.S. Koka. "Induction characterization and Targeting of Hematopoietic cancer stem cells". J. Stem Cells, vol. 5, no. 1, pp. 1-7, 2010.
44. G.L. Eiben, M.P. Velders and W.M. Kast. "The cell - mediated Immune response to human papillomavirus-induced cervical cancer: Implication for Immunotherapy". Adv Cancer Res, pp.113-148, 2002.
45. M.E.G. Boursnell, E. Rutherford, J.K. Hickling, E.A. Rollinson, A.J. Munro, N. Rolley, C.S McLean, L.K. Borysiewicz, K. Vousden, and S.C. Inglis. "Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer". Vaccine, vol. 14, pp.1485-1494, 1996.
46. K.Y. Lin, F.G. Guarnieri, K.F. Staveley-O'Carroll, H.I. Levitsky, J.T. August, D.M. Pardoll and T.C. Wu. "Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen". Cancer Res, vol. 56, pp. 21-26, 1996.
47. L.K. Borysiewicz, A. Fiander, M. Nimako, S. Man, G.W. Wilkinson, D. Westmoreland, A.S. Evans, M. Adams, S.N. Stacey, M.E. Boursnell, E. Rutherford, J.K. Hickling and S.C. Inglis. "A recombinant vaccinia virus encoding human papillomavirus types16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer". Lancet vol. 347, pp. 1523-1527, 1996.
48. C.M. Gerard, N. Baudson, K. Kraemer, C. Bruck, N. Garcon, Y. Paterson, Z.K. Pan and D. Pardoll. "Therapeutic potential of protein and adjuvant vaccinations on tumor growth". Vaccine vol. 19, pp. 2583-2589, 2001.
49. T.C. Wu, F.G. Guarnier, K.F. Staveley-O'Carrol, R.P. Viscidi, H.I. Levitsky, L. Hedrick, K.R. Cho, J.T. August and D.M. Pardoll. "Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens". Proc. Natl. Acad. Sci. USA, vol. 92, no.11, pp. 671-11675, 1995.
50. J.T. Schiller and R.B.S. Roden. "Papillomavirus-like particles". Papillomavirus Rep, vol. 6, pp. 121-128, 1995.
51. D.M. Da Silva, D.V. Pastrana, J.T. Schiller and W.M. Kast. "Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus like particle vaccines". Virology, vol. 290, pp. 350-360, 2001.
52. K. Schafer, M. Muller, S. Faath, A. Henn, W. Osen, H. Zentgraf, A. Benner, L. Gissman and I. Jochmus. "Immune response to human papillomavirus 16 L1 E7 chimeric virus Like particles: Induction of cytotoxic T cells and specific tumor protection". Int. J. Cancer, vol. 81, pp. 881-888, 1999.
53. C. Dupuy, D. Buzoni-Gatel, A. Touze, P. Le Cann, D. Bout and P. Coursaget. "Cell mediated immunity induced in mice by HPV16 L1 virus like particles". Microbiol. Pathogen, vol. 22, pp. 219-225, 1997.
54. S. Peng, I.H. Frazer, G.J. Fernandoand, J. Zhou. "Papillomavirus virus like particles can deliver defined CTL epitopes to the MHC class I pathway". Virology, vol. 240, pp.147-157, 1998.
55. H.L. Greenstone, J.D. Nieland, K.E. de Visser, M.L. De Bruijn, R. Kirnbauer, R.B.S. Roden, D.R. Lowry, W.M. Kast and J.T. Schiller. "Chimeric papillomavirus virus like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model".Proc.natl. Acad. Sci. USA, vol. 95, pp.1800-1805, 1998.
56. M.C.W. Feltkamp, H.L. Smits, M.P.M. Vierboom, R.P. Minnaar, B.M. de Jongh, J.M. Drijfhout, J. ter Schegget, C.J.M Melief and W.M. Kast. "Vaccination with cytotoxic T lymphocytes epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells". Eur.J. Immunol, vol. 23, pp. 2242-2249, 1993.
57. M.S. Campo, G.J. Grindley, B.W. O'Neil, L.M. Chandrachud, G.M. McGarvie and W.F. Jarret. "Prophylactic and therapeutic vaccination against mucosal papillomavirus". J. Gen. Virol, vol. 74, PT 6, pp. 945-953, 1993.
58. M.A. Ossevoort, M.C. Feltkamp, K.J. van Veen, C.J.M. Melief and W.M. Kast. "Dendriticcells as carriers for a cytotoxic T-lymphocyte epitope based peptide vaccine in protection against a human papillomavirus type 16 - induced tumor". J. Immunother, vol.18, pp. 86-94, 1995.
59. T. Tuting, A. Gambotto, A. Deleo, M.T. Lotze, P.D. Robbins and W.J. Storkus. "Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice". Cancer Gene Ther, vol. 6, pp.73-80, 1999.
60. H. zur Hausen. "Papillomaviruses-Vaccination and Beyond". Biochemistry (Moscow) Russian in Biokhimiya, vol. 73, no. 5, pp. 619-626, 2008.
61. Cid-Arregui, V. Juarez and H. Zur Hausen. "The Synthetic E7 Gene of Human papillomavirus type 16 that yields enhanced expression of the Protein in Mammalian cells and is Useful for DNA immunization studies". J. Virol, vol. 77, no.8, pp. 4928-4937, 2003.
62. Y. Ye, W. Xu, W. Zhong, Y. Li, and C. Wang. "Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down regulation and Caspases activation". Mol. Cell Biochem, vol. 363, no.1-2, pp. 191-202, 2012.
63. H.S. Jung, O.C. Erkin, M.J. Kwon, S.H. Kim, J.I. Jung, Y.K. Oh, S.W. Her, W. Ju, Y.L. Choi, S.Y. Song, J.K. Kim, Y.D. Kim, G.Y. Shim, Y.K. Shin. "The synergistic therapeutic effect of cisplatin with Human Papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo". Int. J. Cancer, vol. 130, no. 8, pp. 1925-36, (2012).
64. J. Zhou, C. Peng, B. Li, F. Wang, C. Zhou, D. Hong, F. Ye, X. Cheng, W. Lu, X. Xie. "Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol. Oncol, vol. 124, no.2, pp. 296-302, 2012.
65. W.L. Liu, N. Green, L.W. Seymour, M. Stevenson. "Paclitaxel combined with siRNA targeting HPV16 Oncogenes improves cytoxicity for cervical carcinoma". Cancer Gene Ther, vol. 16, no.10, pp. 764-75, 2009.
66. R. Koivusalo, E. Krausz, H. Helenius, S. Hietanen. "Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: Opposite effect of siRNA in combination with different drugs". Mol. Pharmacol, vol. 68, no.2, pp. 372-82, 2005.
67. M.J. Caballero, A. Garzon, L. Gonzalez-Cintado, W. Kowalczyk, I. Jimenez Torres, G. Calderita, M. Rodriguez, V. Gondar, J.J. Bernal, C. Ardavin, D. Andrew, T. Zurcher, C. Von Kobbe. "Chimeric infectious bursal disease virus like particlesas potent vaccines for eradication of established HPV 16 E7 dependent tumors". PLos One, vol. 7, no.12, pp. 1-12, 2012.
68. T. Ishiwata, Y. Matsuda and Z. Naito. "Nestin in gastrointestinal and other cancers: effects on cell and tumor angiogenesis". World J. Gastroentrol, vol. 17, no.4, pp. 409-18, 2011.
69. K. Astbury, L. McEvoy, H. Brian, C. Spillane, O. Sheils, C. Martin, J.J. O' Leary. " MYBL2 (B-MYB) in cervical cancer: putative biomarker". Int. J. Gynecol Cancer, vol. 21, no.2, pp. 206-12, 2011
70. S. Guenin, M. Mouallif, R. Deplus, X. Lampe, N. Krusy, E. Calonne, K. Delbecque, F. Kridelka, F. Fuks, M.M. Ennaji, P. Delvenne. "Abberrant promoter methylation and expression of UTF1 during cervical carcinogenesis". PLoS One, vol.7, no.8, pp.1-11, 2012.
71. J.Y. Song, H.S. Bae, D.H. Koo, J.K. Lee, H.H. Jung, K.W. Lee, N.W. Lee. "Candidates for tumor markers of cervical cancer discovered by Proteomic Analysis". J. Korean. Med. Sci, vol. 27, pp. 1479-1485, 2012.
72. K.H. Vousden. "Interactions between papillomavirus proteins and tumor suppressor gene products". Adv Cancer Res, vol. 64, pp. 1-24, 1994.
73. S. Kanodia, D.M. Da Silva, T Karamanukyan, L. Bogaert, Y.X. Fu, W.M. Kast. " Expression of LIGHT/ TNFSF 14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression". Cancer Res. 70 (10): 3955-64, 2010.
74. L. Wang, H. Guo, L. Yang, L. Dong, C. Lin, J. Zhang, P. Lin, X. Wang. Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-kB activity and apoptosis induction. Mol. Cell. Biochem. 379(1-2):7-18, 2013.